AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
Purpose of Study:
This study is called a clinical trial. A clinical trial is a research study involving treatment of a disease in human patients. This study is organized by Children’s Oncology Group (COG). COG is an international research group that conducts clinical trials for children with cancer. More than 200 hospitals in North America, Australia, New Zealand, and Europe are members of COG.
How long is the study?
We would like to continue to follow your health status for about 10 years after you enter the study.
Who can participate:
Patients must have newly diagnosed Standard Risk B-ALL or B-LLy Murphy Stages I or II. Patients with Down syndrome are also eligible.
Patients must be > 365 days and < 10 years of age (for B-ALL patients)
Patients must be >365 days and ≤ 30.99 years of age (for B-LLy patients)
What will happen during the study:
Induction – Part I
This study is being done in multiple parts. The purpose of Induction is to collect information on leukemia and the effects of the treatment that will be given. This will be given for 4 weeks. The chemotherapy given during Induction is the current recommended treatment for Standard Risk (SR) B-ALL.
Post Induction – Part II
In the remainder of therapy called post-Induction, we try to get rid of any remaining leukemia cells to keep the leukemia from coming back. This portion of therapy is broken up into 2 segments. The first more intense portion consists of Consolidation, Interim Maintenance (I & II) and Delayed Intensification. The last portion is called Maintenance. All stages of treatment are very important.
Part II is for the first more intense portion of therapy, which lasts approximately 7 months. A final consent describing Maintenance therapy will be discussed with you by your doctor prior to the beginning of Maintenance.
Who to contact:
Mark Ranalli, MD